Slightly less than a year after GlaxoSmithKline ($GSK) and Amicus Therapeutics ($FOLD) reported a failure in their Phase III program for the Fabry disease drug Amigal, the pharma giant has bowed out of the development collaboration. GSK is handing over a check for $3 million to Amicus for a small equity stake and giving up its codevelopment and commercialization rights in exchange for a royalty on any future sales. Report